MedTrace Logo

Pilot Study of Duloxetine in Psychological Resilience

NCT00331799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.

Conditions

Interventions

DRUG

Duloxetine

Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.

Sponsors & Collaborators

Principal Investigators

  • Wei Zhang, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-05-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331799 on ClinicalTrials.gov